Publicacións nas que colabora con Rebeca Fraga Iriso (8)

2023

  1. Preoperative optimization of patients with inflammatory bowel disease: a multicentre study of EIGA Group

    JOURNAL OF CROHNS & COLITIS, Vol. 17, Núm. Supl 1, pp. I356

2022

  1. TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care

    JOURNAL OF CROHNS & COLITIS, Vol. 16, Núm. Supl 1, pp. I314-I315

2019

  1. Letter: double‐dose intensification – a quick way to reverse antibody formation and loss of response in patients treated with adalimumab

    Alimentary Pharmacology & Therapeutics, Vol. 49, Núm. 6, pp. 821-822

2018

  1. N037 Attitudes of Crohn’s disease patients toward self-monitoring trough an App

    Journal of Crohn's and Colitis, Vol. 12, Núm. supplement_1, pp. S585-S585

2016

  1. P521. Anti-TNF serum level and clinical, radiological or endoscopical response in luminal and perianal Crohn’s disease: results of the OPTIMIZA study

    Journal of Crohn's and Colitis, Vol. 10, Núm. suppl 1, pp. S364.1-S364

2015

  1. P408. Differences in biologic efficacy and dose-escalation among anti-TNF agents in Crohn's disease and ulcerative colitis

    Journal of Crohn's and Colitis, Vol. 9, Núm. suppl 1, pp. S283-S283

  2. P526. Impact of postinduction infliximab trough level and disease activity on primary response in Crohn's Disease

    Journal of Crohn's and Colitis, Vol. 9, Núm. suppl 1, pp. S342-S343

2014

  1. Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease

    Gastroenterology, Vol. 146, Núm. Suppl. 1, pp. 247